Study of Resource Allocation for 5G URLLC/eMBB-Oriented Power Hybrid Service.

With the rapid development of the 5G power Internet of Things (IoT), new power systems have higher requirements for data transmission rates, latency, reliability, and energy efficiency. Specifically, the hybrid service of enhanced mobile broadband (eMBB) and ultra-reliable low-latency communication (URLLC) has brought new challenges to the differentiated service of the 5G power IoT. To solve the above problems, this paper first constructs a power IoT model based on NOMA for the mixed service of URLLC and eMBB. Considering the shortage of resource utilization in eMBB and URLLC hybrid power service scenarios, the problem of maximizing system throughput through joint channel selection and power allocation is proposed. The channel selection algorithm based on matching as well as the power allocation algorithm based on water injection are developed to tackle the problem. Both theoretical analysis and experimental simulation verify that our method has superior performance in system throughput and spectrum efficiency.

Tuning Particle Sizes and Active Sites of Ni/CeO2 Catalysts and Their Influence on Maleic Anhydride Hydrogenation.

Supported metal catalysts are widely used in industrial processes, and the particle size of the active metal plays a key role in determining the catalytic activity. Herein, CeO2-supported Ni catalysts with different Ni loading and particle size were prepared by the impregnation method, and the hydrogenation performance of maleic anhydride (MA) over the Ni/CeO2 catalysts was investigated deeply. It was found that changes in Ni loading causes changes in metal particle size and active sites, which significantly affected the conversion and selectivity of MAH reaction. The conversion of MA reached the maximum at about 17.5 Ni loading compared with other contents of Ni loading because of its proper particle size and active sites. In addition, the effects of Ni grain size, surface oxygen vacancy, and Ni-CeO2 interaction on MAH were investigated in detail, and the possible mechanism for MAH over Ni/CeO2 catalysts was deduced. This work greatly deepens the fundamental understanding of Ni loading and size regimes over Ni/CeO2 catalysts for the hydrogenation of MA and provides a theoretical and experimental basis for the preparation of high-activity catalysts for MAH.

Crystal-Plane and Shape Influences of Nanoscale CeO2 on the Activity of Ni/CeO2 Catalysts for Maleic Anhydride Hydrogenation.

Through use of the hydrothermal technique, various shaped CeO2 supports, such as nanocubes (CeO2-C), nanorods (CeO2-R), and nanoparticles (CeO2-P), were synthesized and employed for supporting Ni species as catalysts for a maleic anhydride hydrogenation (MAH) reaction. The achievements of this characterization illustrate that Ni atoms are capable of being incorporated into crystal lattices and can occupy the vacant sites on the CeO2 surface, which leads to an enhancement of oxygen vacancies. The results of the MAH reaction show that the morphology and shape of CeO2 play an important role in the catalytic performance of the MAH reaction. The catalyst for the rod-like CeO2-R obtains a higher catalytic activity than the other two catalysts. It can be concluded that the higher catalytic performances of rod-like CeO2-R sample should be attributed to the higher dispersion of Ni particles, stronger support-metal interaction, more oxygen vacancies, and the lattice oxygen mobility. The research on the performances of morphology-dependent Ni/CeO2 catalysts as well as the relative reaction strategy of MAH will be remarkably advantageous for developing novel catalysts for MA hydrogenation.

Evaluation of liver regeneration and post-hepatectomy liver failure after hemihepatectomy in patients with hepatocellular carcinoma.

Aim: To explore clinical factors associated with extent of liver regeneration after hemihepatectomy to treat hepatocellular carcinoma (HCC).Methods: Future liver remnant volume (as a percentage of functional liver volume, %FLRV) and remnant liver volume were measured preoperatively and at 1, 5, 9, and 13 weeks postoperatively.Results: After hepatectomy, 1 of 125 patients (0.8%) died within 3 months, 13 (10.4%) experienced liver failure, and 99 (79.2%) experienced complications. %FLRV was able to predict liver failure with an area under the receiver operating characteristic curve of 0.900, and a cut-off value of 42.7% showed sensitivity of 85.7% and specificity of 88.6%. Postoperative median growth ratio was 21.3% at 1 week, 30.9% at 5 weeks, 34.6% at 9 weeks, and 37.1% at 13 weeks. Multivariate analysis identified three predictors associated with liver regeneration: FLRV < 601 cm3, %FLRV, and liver cirrhosis. At postoperative weeks (POWs) 1 and 5, liver function indicators were significantly better among patients showing high extent of regeneration than among those showing low extent, but these differences disappeared by POW 9.Conclusions: FLRV, %FLRV, and liver cirrhosis strongly influence extent of liver regeneration after hepatectomy. %FLRV values below 42.7% are associated with greater risk of post-hepatectomy liver failure.

[The scalp localization system of neurosurgery based on augmented reality theory].

Neurosurgery navigation system, which is expensive and complicated to operate, has a low penetration rate, and is only found in some large medical institutions. In order to meet the needs of other small and medium-sized medical institutions for neurosurgical navigation systems, the scalp localization system of neurosurgery based on augmented reality (AR) theory was developed. AR technology is used to fuse virtual world images with real images. The system integrates computed tomography (CT) or magnetic resonance imaging (MRI) with the patient's head in real life to achieve the scalp positioning. This article focuses on the key points of Digital Imaging and Communications in Medicine (DICOM) standard, three-dimensional (3D) reconstruction, and AR image layer fusion in medical image visualization. This research shows that the system is suitable for a variety of mobile phones, can achieve two-dimensional (2D) image display, 3D rendering and clinical scalp positioning application, which has a certain significance for the auxiliary neurosurgical head surface positioning.

Efficacy and Safety of Lumboperitoneal Shunt in the Treatment of All-Cause Communicating Hydrocephalus: Analysis of Risk Factors of Shunt Failure.

OBJECTIVE: To analyze the outcomes of use of a lumboperitoneal shunt (LPS) to treat all-cause communicating hydrocephalus (ACCH). METHODS: We analyzed the outcomes of adult patients with ACCH treated with an LPS between June 2015 and June 2018, using Keifer's hydrocephalus score (KHS), postoperative symptom improvement score (SIS), and the Evans index for 5 days after surgery. All patients were followed up to assess long-term outcomes and quality of life. Based on the follow-up data in shunt successful (SS) patients and shunt failure (SF) patients, multivariate analysis with binary logistic regression was used to identify risk factors for LPS failure. RESULTS: A total of 71 eligible patients were included in this study. The KHS (mean, 8.31 ± 4.80 vs. 3.65 ± 3.08; P < 0.001) and Evans index (mean, 0.35 ± 0.05 vs. 0.28 ± 0.05; P < 0.001) were significantly improved following LPS. However, the overall incidence of complications was 40.8%. According to follow-up data, 18 patients (25.4%) failed; the most common reason for failure was catheter obstruction. The majority of patients obtain good prognosis with low level of RBCs counts in CSF (P = 0.039) and postoperative Evans index (P = 0.046) were statistically different between SS and SF group. The multivariate analysis identified elevated RBC count in CSF as a dependent risk factor for LPS failure (odds ratio, 24.111; 95% confidence interval, 2.611-222.629; P = 0.005). CONCLUSIONS: Our findings indicate that LPS may be a promising option for the treatment of ACCH.

One-year outcome of patients with posttraumatic hydrocephalus treated by lumboperitoneal shunt: an observational study from China.

BACKGROUND: Lumboperitoneal shunt (LPS) attracts increasing number of research interest in the treatment of hydrocephalus due to minimal invasiveness. However, the outcome of LPS-treated posttraumatic hydrocephalus (PTH) is poorly learnt, remaining unknown to date. METHODS: We retrospectively analyzed adult patients with PTH treated by LPS in our department between May 2013 and Apr 2017. Baseline characteristics, preoperative clinical features, symptomatic and imageologic improvement, and postoperative complications were synchronously investigated. All patients were followed up to 1 year after LPS to determine the shunt outcome and quality of life. Furthermore, the Kaplan-Meier curve was drawn and binary logistic regression analysis was used to identify the possible predictive factors of shunt failure. RESULTS: Thirty-eight eligible patients were included in our study. Five days after LPS, chronic hydrocephalus scores (CHS; 10.26 ± 5.17 vs 5.21 ± 3.75; P < 0.001) and Evans index (0.36 ± 0.06 vs 0.28 ± 0.06; P < 0.001) were significantly improved with statistical difference. The overall incidence of complications was 50% (19 patients) while hydrocephalus-associated death or shunt failure was not observed immediately after LPS. According to the 1-year follow-up, most of the patients obtained good prognosis while 16 patients (42.1%) were failed, including 15 patients (39.5%) underwent shunt revision and one patient (2.6%) was dead ascribing to shunt malfunction. However, we failed to screen out any factors contributing to LPS failure. CONCLUSION: To sum up, we have, for the first time, demonstrated that LPS could be a potential option to treat PTH.

Establishing a Preoperative Evaluation System for Lumboperitoneal Shunt: Approach to Attenuate the Risk of Shunt Failure.

OBJECTIVE: Lumboperitoneal shunt (LPS) has been demonstrated an effective method for the treatment of communicating hydrocephalus in the presence of frequent shunt failure. The objective of the present study was to determine whether establishing a preoperative evaluation system could benefit patients, thus attenuating the risk of LPS failure. METHODS: In this 3-year study, treated by LPS, patients undergoing preoperative evaluation were included into the study group and other individuals without preoperative evaluation were included into the control group. Perioperative conditions, including Keifer's hydrocephalus score, symptomatic control rate, Evans index, complications, long-term shunt revision rate, and quality of life, were synchronously investigated. RESULTS: A total of 93 eligible patients were included in the study (study group, 51; control group, 42). The baseline characteristics of the 2 groups were basically similar. The results showed that patients in the study group had better short-term improvement in symptoms and imageology, including higher symptomatic control rate (median, 62.5% vs. 50%; P = 0.001), more reduction in Evans index (0.08 ± 0.05 vs. 0.05 ± 0.04; P = 0.002), and lower incidence of postoperative complications (median, 35.3% vs. 57.1%; P = 0.04). Similarly, the incidence of shunt revision in the study group was dramatically lower than in the control group (median, 15.7% vs. 40.9%; P = 0.006) in line with the revision-free curve (P = 0.002), which suggested that most of patients received revision, if needed, within 3 months. In addition, patients in the study group had better quality of life. CONCLUSIONS: In conclusion, patients who underwent evaluation before LPS had better short-term and long-term outcomes, suggesting that it would be a promising strategy to correctly select patients for LPS with prolonged favorable shunt outcomes.

WDL-RF: predicting bioactivities of ligand molecules acting with G protein-coupled receptors by combining weighted deep learning and random forest.

Motivation: Precise assessment of ligand bioactivities (including IC50, EC50, Ki, Kd, etc.) is essential for virtual screening and lead compound identification. However, not all ligands have experimentally determined activities. In particular, many G protein-coupled receptors (GPCRs), which are the largest integral membrane protein family and represent targets of nearly 40% drugs on the market, lack published experimental data about ligand interactions. Computational methods with the ability to accurately predict the bioactivity of ligands can help efficiently address this problem. Results: We proposed a new method, WDL-RF, using weighted deep learning and random forest, to model the bioactivity of GPCR-associated ligand molecules. The pipeline of our algorithm consists of two consecutive stages: (i) molecular fingerprint generation through a new weighted deep learning method, and (ii) bioactivity calculations with a random forest model; where one uniqueness of the approach is that the model allows end-to-end learning of prediction pipelines with input ligands being of arbitrary size. The method was tested on a set of twenty-six non-redundant GPCRs that have a high number of active ligands, each with 200-4000 ligand associations. The results from our benchmark show that WDL-RF can generate bioactivity predictions with an average root-mean square error 1.33 and correlation coefficient (r2) 0.80 compared to the experimental measurements, which are significantly more accurate than the control predictors with different molecular fingerprints and descriptors. In particular, data-driven molecular fingerprint features, as extracted from the weighted deep learning models, can help solve deficiencies stemming from the use of traditional hand-crafted features and significantly increase the efficiency of short molecular fingerprints in virtual screening. Availability and implementation: The WDL-RF web server, as well as source codes and datasets of WDL-RF, is freely available at https://zhanglab.ccmb.med.umich.edu/WDL-RF/ for academic purposes. Supplementary information: Supplementary data are available at Bioinformatics online.

A Large Multicenter Retrospective Research on Embedded Cranioplasty and Covered Cranioplasty.

OBJECTIVE: Cranioplasty (CP) can be either embedded or covered, according to the implants used. However, determining which one is better in treating cranial defects is difficult. This study aimed to compare the clinical outcomes and complications of embedded CP and covered CP. METHODS: A multicenter retrospective study was undertaken with patients who underwent CP with polyetheretherketone (PEEK) implants and titanium implants between January 2014 and March 2017. The medical records of these patients were reviewed retrospectively and analyzed statistically. RESULTS: There were 185 patients, including 75 patients (40.5%) who underwent embedded CP with PEEK implants (PEEK group) and 110 patients (59.5%) who underwent covered CP using titanium mesh (titanium group), in this study. Compared with the titanium group, the incidence of overall complications (P = 0.03), postoperative new seizures (P = 0.01), postoperative implant exposure (P = 0.03), and reoperation (P = 0.01) was significantly lower in PEEK group. The rate of brain function improvement (P = 0.01) after CP and satisfaction with CP (P = 0.01) in patients in the PEEK group were higher than that in the titanium group. CONCLUSIONS: Our results show that embedded CP with PEEK has a distinct advantage in brain function improvement and fewer postoperative complications compared with covered CP with titanium mesh. However, the high cost of PEEK is an obvious drawback. This study can help both neurosurgeons and patients in choosing a better therapeutic method to achieve the most satisfactory outcome in treating cranial defects.

Effects of antiviral therapy on post-hepatectomy HBV reactivation and liver function in HBV DNA-negative patients with HBV-related hepatocellular carcinoma.

The ability of antiviral therapy to reduce risk of post-hepatectomy hepatitis B virus (HBV) reactivation in patients negative for viral DNA is unclear. This prospective study involved 174 consecutive patients with hepatitis B virus related hepatocellular carcinoma who were negative for hepatitis B virus DNA in serum and who underwent hepatic resection. Hepatitis B virus reactivation occurred in 30 patients in the non-antiviral group (27.8%) but in only 2 patients in the antiviral group (3.0%, P < 0.001). Based on multivariate analysis, risk of hepatitis B virus reactivation was associated with minor hepatectomy and absence of antiviral therapy. Liver function indicators at one week after resection did not differ significantly between the two groups, or between patients who experienced hepatitis B virus reactivation or not. Nevertheless, alanine aminotransferase and albumin at 1 month after resection were significantly higher in the antiviral group than in the non-antiviral group, and they were significantly higher in patients who did not experience hepatitis B virus reactivation than in those who did. Therefore, patients with hepatitis B virus related hepatocellular carcinoma face substantial risk of hepatitis B virus reactivation after hepatectomy, even if they are negative for viral DNA at baseline. Antiviral therapy can reduce the risk of reactivation, helping improve liver function after surgery.

Try113His and His139Arg polymorphisms in the microsomal epoxide hydrolase gene are not associated with risk of breast cancer.

Breast cancer may be caused by several factors, including polymorphisms in the microsomal epoxide hydrolase (mEH) gene. Previous work suggested an association between mEH polymorphism and risk of breast cancer, but the results have been inconsistent. PubMed, EMBASE, Google Scholar, and the Chinese National Knowledge Infrastructure database were systematically searched to identify relevant studies. A meta-analysis was performed to examine the association between Tyr113His and His139Arg mEH polymorphisms and susceptibility to breast cancer. Odds ratios (ORs) with 95 % confidence intervals (CIs) were calculated to assess the strength of the association. Seven studies involving 6,357 cases and 8,089 controls were included in this study. The Tyr113His mEH polymorphism did not affect breast cancer risk in the allelic contrast model (OR = 0.99, 95 % CI = 0.94-1.04, P = 0.58), the dominant genetic model (OR = 1.14, 95 % CI = 0.88-1.48, P = 0.33), or the recessive genetic model (OR = 1.03, 95 % CI = 0.96-1.10, P = 0.43). Similarly, the His139Arg mEH polymorphism was not associated with breast cancer risk in the allelic contrast model (OR = 0.97, 95 % CI = 0.91-1.04, P = 0.44), the dominant genetic model (OR = 1.01, 95 % CI = 0.84-1.21, P = 0.94), or the recessive genetic model (OR = 1.04, 95 % CI = 0.96-1.12, P = 0.35). The mEH polymorphisms Tyr113His and His139Arg are not risk factors for breast cancer. Further, large and well-designed studies are required to confirm this conclusion.

Single nucleotide polymorphism 8q24 rs13281615 and risk of breast cancer: meta-analysis of more than 100,000 cases.

BACKGROUND: The onset and progression of breast cancer (BC) is influenced by many factors, including the single nucleotide polymorphism (SNP) rs13281615 at 8q24. However, studies of the potential association between rs13281615 at 8q24 and risk of BC have given inconsistent results. We performed a meta-analysis to address this controversy. METHODS: PubMed, EMBASE and the Chinese National Knowledge Infrastructure databases were systematically searched to identify relevant studies. Two curators independently extracted data, and odds ratios (ORs) with 95% confidence intervals (95% CIs) were calculated to assess the strength of the association between rs13281615 at 8q24 and risk of BC. RESULTS: Fourteen studies are included in the meta-analysis, involving 44,283 cases (5,170 Chinese and 39,113 mixed) and 55,756 controls (5,589 Chinese and 50,167 mixed). The GG and G-allele genotypes of rs13281615 at 8q24 are significantly associated with increased risk of BC (GG vs. AG+AA, OR 1.13, 95% CI 1.08-1.19, P<0.001; G-allele vs. A-allele, OR 1.10, 95% CI 1.06-1.14, P<0.001; GG vs. AA, OR 1.20, 95% CI 1.12-1.29, P<0.001). Conversely, the AA genotype is significantly associated with decreased risk of BC (AA vs. AG+GG, OR 0.89, 95% CI 0.84-0.93, P<0.001). CONCLUSION: G-allele genotypes of rs13281615 at 8q24 polymorphism are a risk factor for developing BC, while the AA genotype is a protective factor. Further large and well-designed studies are required to confirm this conclusion.